GSK catalyst calendar
Clinical trials led by listed companies, by the completion date the sponsor registered on ClinicalTrials.gov, soonest first, from today. Most future dates are the sponsor's estimate and can move.
- Completion LockedPhase 1NCT07428759Trial to Evaluate Safety and Immune Response of an Investigational Pneumococcal Vaccine in Adults Aged 50 To 64 YearsGlaxoSmithKline · Pneumonia, BacterialActive, not recruitingGSKLead
- Enrollment
- Locked
- Primary completion
- Nov 19, 2026Sponsor estimate
- Interventions
- Locked
- Completion LockedPhase 3NCT06693895A Study on the Safety of an Investigational Chickenpox Vaccine, When Given to Healthy Children, 12 to 15 Months of AgeGlaxoSmithKline · ChickenpoxRecruitingGSKLead
- Enrollment
- Locked
- Primary completion
- Nov 23, 2026Sponsor estimate
- Interventions
- Locked
- Completion LockedPhase 3NCT03981796A Study to Evaluate Dostarlimab Plus Carboplatin-paclitaxel Versus Placebo Plus Carboplatin-paclitaxel in Participants With Recurrent or...Tesaro, Inc. · NeoplasmsActive, not recruitingGSKLead
- Enrollment
- Locked
- Primary completion
- Nov 26, 2026Sponsor estimate
- Interventions
- Locked
- Completion LockedPhase 2NCT04165772Study of Induction PD-1 Blockade in Subjects With Locally Advanced Mismatch Repair Deficient Solid TumorsMemorial Sloan Kettering Cancer Center · Rectal AdenocarcinomaRecruitingGSKCollaborator
- Enrollment
- Locked
- Primary completion
- Nov 30, 2026Sponsor estimate
- Interventions
- Locked
- Completion LockedNo phase registeredNCT00825929Pharmacokinetics of Antiretroviral Agents in HIV-infected Pregnant Women.Radboud University Medical Center · HIV Infections
- Enrollment
- Locked
- Primary completion
- Dec 2026Sponsor estimate
- Interventions
- Locked
- Completion LockedPhase 2NCT03016338Study of Niraparib and TSR-042 in Recurrent Endometrial CancerUniversity Health Network, Toronto · Endometrial CancerActive, not recruitingGSKCollaborator
- Enrollment
- Locked
- Primary completion
- Jan 5, 2021Actual
- Interventions
- Locked
- Completion LockedPhase 1/Phase 2NCT05002816Novel Combination of Belantamab Mafodotin and Elotuzumab to Enhance Therapeutic Efficacy in Multiple MyelomaYale University · Multiple MyelomaActive, not recruitingGSKCollaborator
- Enrollment
- Locked
- Primary completion
- Jan 22, 2026Actual
- Interventions
- Locked
- Completion LockedNo phase registeredNCT06389058Using NLP and Neural Networks to Autonomously Identify Severe Asthma and Determine Study Eligibility in a Large Healthcare SystemSan Diego State University · Severe AsthmaActive, not recruitingGSKCollaborator
- Enrollment
- Locked
- Primary completion
- Dec 2026Sponsor estimate
- Interventions
- Locked
- Completion LockedNo phase registeredNCT06489964Addressing Unfunded Vaccines Through a Co-payment Mechanism in PharmaciesCanadian Immunization Research Network · Preventable Disease, VaccineRecruitingAZNCollaboratorGSKCollaborator
- Enrollment
- Locked
- Primary completion
- Dec 2026Sponsor estimate
- Interventions
- Locked
- Completion LockedNo phase registeredNCT06911775Eosinophil Subpopulations in Eosinophilic-associated DiseasesUniversity of Florence · Eosinophilic AsthmaNot yet recruitingGSKCollaborator
- Enrollment
- Locked
- Primary completion
- Jul 2026Sponsor estimate
- Interventions
- Locked
- Completion LockedPhase 2NCT03983993Niraparib and Panitumumab in Patients With Advanced or Metastatic Colorectal CancerEmory University · Advanced Microsatellite Stable Colorectal CarcinomaActive, not recruitingGSKCollaborator
- Enrollment
- Locked
- Primary completion
- May 17, 2023Actual
- Interventions
- Locked
- Completion LockedPhase 1NCT06154837A Study for GSK3862995B in Healthy Participants and Participants With Chronic Obstructive Pulmonary DiseaseGlaxoSmithKline · Pulmonary Disease, Chronic ObstructiveActive, not recruitingGSKLead
- Enrollment
- Locked
- Primary completion
- Dec 16, 2026Sponsor estimate
- Interventions
- Locked
- Completion LockedNo phase registeredNCT07017803Molecular Epidemiology, Strains Genotyping of Multi-drug Resistant Tuberculosis Circulating in Central Africa RegionCentre de Recherche Médicale de Lambaréné · Multidrug-resistant Tuberculosis (MDR-TB)RecruitingGSKCollaborator
- Enrollment
- Locked
- Primary completion
- Nov 30, 2026Sponsor estimate
- Interventions
- Locked
- Completion LockedPhase 2NCT04641247A Long-term Treatment Extension Study of Niraparib in Participants Who Completed a Prior GlaxoSmithKline/TESARO-sponsored Niraparib StudyGlaxoSmithKline · Ovarian NeoplasmsRecruitingGSKLead
- Enrollment
- Locked
- Primary completion
- Dec 28, 2026Sponsor estimate
- Interventions
- Locked
- Completion LockedPhase 3NCT07645248A Study to Compare Safety of 4 Weeks Exposure to Propellants Hydrofluoroalkane 1,1-difluoroethane (HFA-152a) and...GlaxoSmithKline · AsthmaRecruitingGSKLead
- Enrollment
- Locked
- Primary completion
- Dec 28, 2026Sponsor estimate
- Interventions
- Locked
- Completion LockedPhase 1NCT04446351Study of the Safety and Effectiveness of GSK6097608 in Participants With Advanced Solid TumorsGlaxoSmithKline · NeoplasmsActive, not recruitingGSKLead
- Enrollment
- Locked
- Primary completion
- Dec 31, 2026Sponsor estimate
- Interventions
- Locked
- Completion LockedNo phase registeredNCT06635421The Expand Study-Pharmacist Administered Long Acting Cabotegravir + Rilpivirine to Expand Access for People With HIVMetroHealth Medical Center · HIV I InfectionNot yet recruitingGSKCollaborator
- Enrollment
- Locked
- Primary completion
- Dec 31, 2026Sponsor estimate
- Interventions
- Locked
- Completion LockedNo phase registeredNCT06702345Clostridioides Difficile Controlled Human Infection ModelLeiden University Medical Center · C. DifficileNot yet recruitingGSKCollaborator
- Enrollment
- Locked
- Primary completion
- Jul 1, 2026Sponsor estimate
- Interventions
- Locked
- Completion LockedPhase 3NCT07220109A Study on the Immune Response and Safety of Vaccine Against Respiratory Syncytial Virus Given to Chinese Adults 18 to 59 Years of Age...GlaxoSmithKline · Respiratory Syncytial Virus InfectionsActive, not recruitingGSKLead
- Enrollment
- Locked
- Primary completion
- Jul 20, 2026Actual
- Interventions
- Locked
- Completion LockedPhase 3NCT07596199A Study on the Immune Response and Safety of a Combined Vaccine Against Diphtheria, Tetanus and Acellular Pertussis (dTpa) in Japanese...GlaxoSmithKline · Diphtheria-Tetanus-acellular Pertussis VaccinesActive, not recruitingGSKLead
- Enrollment
- Locked
- Primary completion
- Nov 23, 2026Sponsor estimate
- Interventions
- Locked
- Completion LockedNo phase registeredNCT07900581Analysis of Whole Exome and Transcriptome Sequencing to Identify Prognostic Biomarkers in Patients With Non-Small Cell Lung Cancer (NSCLC)Hellenic Cooperative Oncology Group · Non-small Cell Lung Cancer (NSCLC)RecruitingGSKCollaborator
- Enrollment
- Locked
- Primary completion
- Dec 31, 2026Sponsor estimate
- Interventions
- Locked
- Completion LockedPhase 1/Phase 2NCT03830918Niraparib, Temozolomide and Atezolizumab in Treating Patients With Advanced Solid Tumors and Extensive-Stage Small Cell Lung Cancer With...Jonsson Comprehensive Cancer Center · Advanced Malignant Solid NeoplasmActive, not recruitingGSKCollaborator
- Enrollment
- Locked
- Primary completion
- Jan 3, 2027Sponsor estimate
- Interventions
- Locked
- Completion LockedPhase 1NCT07862114A Study to Investigate the Effect of Omeprazole and Cyclosporine on Velzatinib in Healthy ParticipantsGlaxoSmithKline · Healthy ParticipantsNot yet recruitingGSKLead
- Enrollment
- Locked
- Primary completion
- Jan 12, 2027Sponsor estimate
- Interventions
- Locked
- Completion LockedPhase 4NCT06897527A Study to Evaluate the Safety of Dostarlimab in Adult Participants in India With Recurrent or Advanced Endometrial Cancer (EC)GlaxoSmithKline · Neoplasms, EndometrialNot yet recruitingGSKLead
- Enrollment
- Locked
- Primary completion
- Jan 13, 2027Sponsor estimate
- Interventions
- Locked
- Completion LockedPhase 3NCT05757102A Study to Compare the Efficacy, Safety and Tolerability of FF/UMEC/VI With FF/VI in 12-17-year-olds With AsthmaGlaxoSmithKline · AsthmaActive, not recruitingGSKLead
- Enrollment
- Locked
- Primary completion
- Jan 26, 2027Sponsor estimate
- Interventions
- Locked
Enrollment, interventions and the start and completion dates are locked on 25 rows here. Included with TrialScanner ($9.99 a month) and Signal8 Pro.
Unlock with TrialScannerShowing the first 25 trials. There are 4 more in this window; the full list is part of TrialScanner.
Unlock with TrialScannerHow to read this calendar
Completion dates as registered on ClinicalTrials.gov by the sponsor, for trials Signal8 links to a listed company. Most future dates are the sponsor's estimate and move. A completion date is when the last participant is measured, not when results are announced.
The window starts today. A date the sponsor registered to the day is listed when it falls inside the window; a date that has already passed is never listed as upcoming, even when the sponsor has not updated it yet. A date registered to the month only (shown as, say, Dec 2026) could be any day of that month, so it is listed only when the whole month falls inside the window. TrialScanner never adds a day the sponsor did not register.
By default the list shows trials where a listed company is the lead sponsor. Trials a listed company only collaborates on (as a partner, drug supplier or contract research organization) are added with the role filter, and every company is labelled Lead or Collaborator.
Free readers see the first 25 trials of any filter and windows up to 90 days, with the trial, phase, status, sponsor and primary completion. Enrollment, interventions, the start and completion dates, longer windows and later pages are part of the plan. See the methodology.